Tag: chief financial officer

Posts Positive Organic Growth and Adjusted EBITDA^‎1 of 23.5% of Revenue

ROCHESTER, N.Y., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 2025 Barclays Global Consumer Staples Conference on Tuesday, September 2, 2025 in Boston, MA. The presentation is scheduled to begin at 3:45 p.m. ET and is expected to cover the company’s financial metrics, operating performance, strategic business initiatives, and outlook for the future.

ARLINGTON, Va., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three and nine months ended June 30, 2025.

Achieves Positive Net Income in the Second Quarter and Positive Adjusted EBITDA¹ for the Second Quarter and Six Months Ended June 30, 2025 

Group Business Leaders Established; Functional Leaders Responsibilities Enhanced

LOS ANGELES, Aug. 10, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 405 owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2025.

NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade” or the “Company”), a technology-powered air mobility platform, today announced that Will Heyburn, Chief Financial Officer, will present at the Oppenheimer 28th Annual Technology, Internet & Communications Conference on Monday, August 11, 2025 at 2:55pm ET. A webcast of the event will be available at the link here. A replay will be available shortly after the conclusion of the presentation on the investor relations section of the Company’s website at https://ir.blade.com/news-events.

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.